Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Imfinzi Shows Efficacy in Treating Small-Cell Lung Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2019 | 04:13am EDT

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) said Monday that a phase 3 clinical trial of drug Imfinzi showed the drug was able to improve survival rates in patients with small-cell lung cancer.

The British pharmaceutical company said that Imfinzi combined with chemotherapy showed a clinically meaningful improvement in overall survival for patients with untreated extensive-stage small-cell lung cancer when compared with standard chemotherapy.

AstraZeneca said that the treatment reduced the risk of death by 27%, with a median overall survival of 13 months versus 10.3 months for the standard of care.

In the study, titled Caspian, 33.9% of patients treated with Imfinzi reached the 18-month survival mark, compared with 24.7% for chemotherapy alone.

Small-cell lung cancer is an aggressive and fast-spreading cancer.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
09/19LONDON MARKETS: U.K. Stocks Snap Three-day Losing Run
DJ
09/18LONDON STOCK EXCHANGE : FTSE 100 lingers in red as Fed decision looms and Kingfi..
RE
09/18IRONWOOD PHARMACEUTICALS : AstraZeneca amends collaboration with Ironwood for Li..
AQ
09/18ASTRAZENECA : amends collaboration with Ironwood for Linzess in China
PU
09/18AstraZeneca Amends China Collaboration Agreement With Ironwood
DJ
09/18ASTRAZENECA : amends collaboration with Ironwood
PU
09/18ASTRAZENECA : amends collaboration with Ironwood for Linzess in China
AQ
09/17LONDON STOCK EXCHANGE : London's FTSE 100 ends on a flat note, Sirius Minerals p..
RE
09/16ASTRAZENECA : FDA Grants Fast Track Designation for Farxiga in Heart Failure
DJ
09/16ASTRAZENECA : redefines cancer treatment with practice-changing data at ESMO 201..
PU
More news
Financials (USD)
Sales 2019 23 963 M
EBIT 2019 6 402 M
Net income 2019 2 299 M
Debt 2019 11 472 M
Yield 2019 3,90%
P/E ratio 2019 40,2x
P/E ratio 2020 28,8x
EV / Sales2019 4,40x
EV / Sales2020 4,01x
Capitalization 94 023 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 93,80  $
Last Close Price 71,67  $
Spread / Highest target 81,0%
Spread / Average Target 30,9%
Spread / Lowest Target -11,7%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA21.35%116 691
JOHNSON & JOHNSON1.05%343 382
ROCHE HOLDING LTD.16.27%243 639
MERCK AND COMPANY9.89%214 995
PFIZER-16.36%201 939
NOVARTIS15.60%198 194